Bibliography
- BROWDER T, FOLKMAN J, PIRIE-SHEPHERD S: Thehemostatic system as a regulator of angiogenesis. J. Biol. Chem. (2000) 275:1521–1524.
- BERGERS G, JAVAHERIAN K, LO KM, FOLKMAN J,HANAHAN D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 284:808–812.
- METZGER RJ, KRASNOW MA: Genetic control ofbranching morphogenesis. Science (1 9 9 9) 284:1635-1639.
- JARECKI J, JOHNSON E, KRASNOW MA: Oxygen regula-tion of airway branching in Drosophila is mediated by branchless FGF. Cell (1999) 99:211–220.
- BENJAMIN LE, GOLIJANIN D, ITIN A, PODE D, KESHET E:Selective ablation of immature blood vessels in established human tumors follows vascular endothe-lial growth factor withdrawal. J. Clin. Invest. (1999) 103:159–165.
- ABRAMOVITCH R, DAFNI H, SMOUHA E, BENJAMIN LE,NEEMAN M: In vivo prediction of vascular suscepti-bility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res. (1 9 9 9) 59:5012-5016.
- CARMELIET P, LAMPUGNANI MG, MOONS et al.: Targeteddeficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell (1999) 98:147–157.
- ILAN N, MAHOOTI S, RIMM DL, MADRI JA: PECAM-1(CD31) functions as a reservoir for and a modulator of tyrosine- phosphorylated beta-catenin. J. Cell ScL (1999) 1 12:3005–3014.
- PEICHEV M, NAIYER AJ, PEREIRA D et al.: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood (2000) 95:952–958.
- LIN Y, WEISDORF DJ, SOLOVEY A, HEBBEL RP: Origins of circulating endothelial cells and endothelial outgrowth from blood [see comments]. J. Clin. Invest. (2000) 105:71–77.
- GALE NW, YANCOPOULOS GD: Growth factors actingvia endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins and ephrins in vascular develop-ment. Genes Dev. (1999) 13:1055–1066.
- HOLASH J, MAISONPIERRE PC, COMPTON D eta].: Vesselcooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science (1 9 9 9) 284:1994-1998.
- SURI C, MCCLAIN J, THURSTON G et al.: Increased vascularization in mice overexpressing angiopoietin-1. Science (1998) 282:468–471.
- THURSTON G, SURI C, SMITH K et al.: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (1999) 286:2511–2514.
- NICOSIA RF, OTTINETTI A: Growth of microvessels inserum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab. Invest. (1990) 63:115–122.
- NICOSIA RF, LIN YJ, HAZELTON D, QIAN X: Endogenousregulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am. J. Pathol (1997) 151:1379–1386.
- AUERBACH R, GILLIGAN B, LU LS, WANG SJ: Cell interac-tions in the mouse yolk sac: vasculogenesis and hematopoiesis. J. Cell Physiol (1997) 173:202–205.
- ZHU Z, LU D, KOTANIDES H, SANTIAGO A et al.: Inhibi-tion of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain- containing receptor antibody. Cancer Lett. (1999) 136:203–213.
- PASQUALINI R, RUOSLAHTI E: Organ targeting in vivo using phage display peptide libraries. Nature (1996) 380:364–366.
- RAJOTTE D, ARAP W, HAGEDORN M, KOIVUNEN E, PASQUALINI R, RUOSLAHTI E: Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. (1998) 102:430–437.
- PASQUALINI R, KOIVUNEN E, KAIN R et al.: Aminopepti-dase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. (2000) 60:722–727.
- ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treatment by targeted drug delivery to tumor vascula-ture in a mouse model. Science (1998) 279:377–380.
- ARAP W, PASQUALINI R, RUOSLAHTI E: Chemotherapytargeted to tumor vasculature. Curr. Opin. Oncol. (1998) 10:560–565.
- ELLERBY HM, ARAP W, ELLERBY LM et al.: Anti-cancer activity of targeted pro-apoptotic peptides. Nature Med. (1999) 5:1032–1038.
- FINE HA, FIGG WD, JAECKLE K et al.: Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas. J. Clin. OncoL (2000) 18:708.